Candida News and Research

RSS

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

American Biotech launches new silver hydrogel wound-dressing products

American Biotech Labs, LLC, is pleased to announce the availability of three new silver hydrogel wound-dressing products.

16 Sep 2014

Unusual kind of immune cell in tongue appears to play pivotal role in prevention of thrush

An unusual kind of immune cell in the tongue appears to play a pivotal role in the prevention of thrush, according to the researchers at the University of Pittsburgh School of Medicine who discovered them.

9 Sep 2014

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm.

21 Aug 2014

Analysis of Candida glabrata fungus mutations reveals new genes that confer anti-fungal tolerance

A group of researchers at the Max F. Perutz Laboratories has created one of the three world's largest gene libraries for the Candida glabrata yeast, which is harmful to humans.

20 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

17 Jul 2014

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.

9 Jul 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.

15 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Extremely premature babies should not be given drug to prevent fatal fungal infection

In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings by a Duke Medicine-led research team.

5 May 2014

Scientists discover protein structure that helps common fungal pathogen to infect humans

A team that includes scientists from the School of Medicine at The University of Texas Health Science Center at San Antonio, Johns Hopkins University and St. Mary's University reported the structure of a protein that helps a common fungus to infect the body.

17 Apr 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida.

14 Mar 2014

Bacterium and fungus partner to cause painful form of tooth decay in preschool children

Early childhood caries, a highly aggressive and painful form of tooth decay that frequently occurs in preschool children, especially from backgrounds of poverty, may result from a nefarious partnership between a bacterium and a fungus, according to a paper published ahead of print in the journal Infection and Immunity.

13 Mar 2014

Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

The gut microbiota contains a vast number of microorganisms from all three domains of life, including bacteria, archaea and fungi, as well as viruses. These interact in a complex way to contribute towards both health and the development of disease - interactions that are only now being elucidated thanks to the application of advanced DNA sequencing technology in this field.

10 Mar 2014

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.

27 Feb 2014

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Led by University of Melbourne PhD candidate Cathy Watson also of the Royal Women's Hospital, the findings were published online in the British Journal of Obstetrics and Gynaecology.

18 Dec 2013

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens.

17 Dec 2013